# Kynam Capital Management, LP 13F Q2 2026: $1.8 billion

Kynam Capital Management, LP reported $1.8 billion in 13F securities across 32 positions for the quarter ended June 30, 2026, in a holdings report filed August 14, 2026. Its largest holding was Celldex Therapeutics Inc New at $198 million, 10.9% of the reported value. Since Q1 2026 it opened 5 new positions and exited 12.

SpecStream is the live web data engine for teams and agents. It reads the SEC's Form 13F data sets each quarter, and this page is that reading, keyed on the manager's CIK and the security's CUSIP. Ask for the managers or the holdings you track, and each new 13F filing arrives in your sheet, CRM, Slack or agent as the SEC publishes it.

- Quarter: Q2 2026, the quarter ended June 30, 2026
- Reported value: $1,809,410,222
- Positions: 32
- Filed: August 14, 2026
- Report type: 13F holdings report
- CIK: 1907884
- Form 13F file number: 028-21939
- CRD number: 314368
- Business address: 221 Elm Road, Princeton, NJ 08540
- SEC filing: [0001907884-26-000012](https://www.sec.gov/Archives/edgar/data/1907884/000190788426000012/0001907884-26-000012-index.htm)

## Top 25 holdings by value

The largest of 32 positions by reported value at the end of the quarter ended June 30, 2026. Put and call options are marked in the class. Change is in shares or principal against the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value | Change since Q1 2026 |
| --- | --- | --- | --- | --- |
| [Celldex Therapeutics Inc New](https://specstream.ai/data/institutional-holders/celldex-therapeutics-inc-new-15117b202) | COM NEW | 5,322,908 | $198.1 million | -517,659 |
| [Syndax Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/syndax-pharmaceuticals-inc-87164f105) | COM | 8,050,959 | $176 million | No change |
| [Vaxcyte Inc](https://specstream.ai/data/institutional-holders/vaxcyte-inc-92243g108) | COM | 2,922,335 | $169.9 million | No change |
| [Cogent Biosciences Inc](https://specstream.ai/data/institutional-holders/cogent-biosciences-inc-19240q201) | COM | 3,667,097 | $141.9 million | -370,234 |
| [Vera Therapeutics Inc](https://specstream.ai/data/institutional-holders/vera-therapeutics-inc-92337r101) | CL A | 2,890,059 | $124 million | -508,165 |
| [Viridian Therapeutics Inc](https://specstream.ai/data/institutional-holders/viridian-therapeutics-inc-92790c104) | COM | 6,453,877 | $118.6 million | +4,112,225 |
| [Travere Therapeutics Inc](https://specstream.ai/data/institutional-holders/travere-therapeutics-inc-89422g107) | COM | 2,000,000 | $113.6 million | +430,982 |
| [Beam Therapeutics Inc](https://specstream.ai/data/institutional-holders/beam-therapeutics-inc-07373v105) | COM | 2,840,792 | $97.5 million | -841,393 |
| [Urogen Pharma LTD](https://specstream.ai/data/institutional-holders/urogen-pharma-ltd-m96088105) | COM | 2,434,207 | $89.6 million | +186,814 |
| [Legend Biotech Corp](https://specstream.ai/data/institutional-holders/legend-biotech-corp-52490g102) | SPONSORED ADS | 3,001,205 | $86.7 million | +1,424,910 |
| [Cytomx Therapeutics Inc.](https://specstream.ai/data/institutional-holders/cytomx-therapeutics-inc-23284f105) | COM | 21,703,093 | $81.4 million | +6,690,000 |
| [Relay Therapeutics Inc](https://specstream.ai/data/institutional-holders/relay-therapeutics-inc-75943r102) | COM | 3,300,000 | $61.7 million | +1,875,741 |
| [Cullinan Therapeutics Inc](https://specstream.ai/data/institutional-holders/cullinan-therapeutics-inc-230031106) | COM | 3,114,132 | $56.7 million | No change |
| [MBX Biosciences Inc](https://specstream.ai/data/institutional-holders/mbx-biosciences-inc-55287l101) | COM | 934,799 | $51.6 million | No change |
| [Immunocore Hldgs PLC](https://specstream.ai/data/institutional-holders/immunocore-hldgs-plc-45258d105) | ADS | 1,375,000 | $43.7 million | +490,063 |
| [Nurix Therapeutics Inc](https://specstream.ai/data/institutional-holders/nurix-therapeutics-inc-67080m103) | COM | 1,194,757 | $29 million | No change |
| [Sutro Biopharma Inc](https://specstream.ai/data/institutional-holders/sutro-biopharma-inc-869367201) | COM SHS | 872,558 | $29 million | No change |
| [Biocryst Pharmaceuticals Inc](https://specstream.ai/data/institutional-holders/biocryst-pharmaceuticals-inc-09058v103) | COM | 2,522,660 | $25.2 million | -3,158,135 |
| [Pharvaris N V](https://specstream.ai/data/institutional-holders/pharvaris-n-v-n69605108) | COM | 661,795 | $22.9 million | +21,400 |
| [Summit Therapeutics Inc](https://specstream.ai/data/institutional-holders/summit-therapeutics-inc-86627t108) | COM | 1,200,000 | $17.5 million | New |
| [Prelude Therapeutics Inc](https://specstream.ai/data/institutional-holders/prelude-therapeutics-inc-74065p101) | COM | 2,415,087 | $12.9 million | +822,536 |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 100,000 | $10.7 million | New |
| Burning Rock Biotech LTD | SPONSORED ADS | 1,238,563 | $10.5 million | +11,008 |
| [Geron Corp](https://specstream.ai/data/institutional-holders/geron-corp-374163103) | COM | 6,836,318 | $8.8 million | No change |
| [Amarin Corp PLC](https://specstream.ai/data/institutional-holders/amarin-corp-plc-023111404) | SPONSORED ADR | 532,982 | $8.5 million | +60,600 |

## New positions in Q2 2026

5 positions not in the filing for the quarter ended March 31, 2026.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| [Summit Therapeutics Inc](https://specstream.ai/data/institutional-holders/summit-therapeutics-inc-86627t108) | COM | 1,200,000 | $17.5 million |
| [Insmed Inc](https://specstream.ai/data/institutional-holders/insmed-inc-457669307) | COM PAR $.01 | 100,000 | $10.7 million |
| [Parabilis Medicines Inc](https://specstream.ai/data/institutional-holders/parabilis-medicines-inc-698955101) | COM | 250,000 | $6.8 million |
| [Engene Therapeutics Inc](https://specstream.ai/data/institutional-holders/engene-therapeutics-inc-29286x101) | COM | 457,855 | $792,089 |
| [Traws Pharma Inc](https://specstream.ai/data/institutional-holders/traws-pharma-inc-68232v884) | COM NEW | 84,400 | $71,175 |

## Positions exited in Q2 2026

12 positions in the filing for the quarter ended March 31, 2026 and not in this one, with the shares and value reported then.

| Issuer | Class | Shares or principal | Value |
| --- | --- | --- | --- |
| Kalvista Pharmaceuticals Inc | COM | 1,820,954 | $36.7 million |
| Apellis Pharmaceuticals Inc | COM | 825,000 | $33.2 million |
| Travere Therapeutics Inc | COM (call) | 800,000 | $23.8 million |
| Revolution Medicines Inc | COM (put) | 207,500 | $20.2 million |
| Soleno Therapeutics Inc | COM | 560,000 | $18.7 million |
| [Evommune Inc](https://specstream.ai/data/institutional-holders/evommune-inc-30054y107) | COM SHS | 625,496 | $14.4 million |
| Engene Holdings Inc | COM | 1,356,843 | $9.2 million |
| [Design Therapeutics Inc](https://specstream.ai/data/institutional-holders/design-therapeutics-inc-25056l103) | COM | 784,606 | $8.3 million |
| [Wave Life Sciences LTD](https://specstream.ai/data/institutional-holders/wave-life-sciences-ltd-y95308105) | SHS | 965,193 | $7 million |
| [Climb Bio Inc](https://specstream.ai/data/institutional-holders/climb-bio-inc-28658r106) | COM | 1,003,341 | $6.9 million |
| [Biohaven LTD](https://specstream.ai/data/institutional-holders/biohaven-ltd-g1110e107) | COM | 702,884 | $5.9 million |
| Travere Therapeutics Inc | COM (put) | 54,900 | $1.6 million |

## Also on SpecStream

- [Kynam Capital Management, LP Form 13F filing on EDGAR](https://www.sec.gov/Archives/edgar/data/1907884/000190788426000012/0001907884-26-000012-index.htm)
- [Largest 13F filers in New Jersey](https://specstream.ai/data/institutional-holdings/state/new-jersey)
- [Largest institutional managers by 13F value](https://specstream.ai/data/institutional-holdings)
- [Most widely held securities in 13F filings](https://specstream.ai/data/institutional-holders)

Source: [the SEC's Form 13F data sets](https://www.sec.gov/data-research/sec-markets-data/form-13f-data-sets). Public data published by the US Securities and Exchange Commission (US government work). Managers report these holdings themselves in Form 13F, and the SEC does not check or guarantee them. Form 13F lists long positions in US listed equities, some options and convertible notes held at the end of the quarter, and leaves out short positions, cash, most bonds and holdings below the reporting threshold. Values are market values in US dollars as the manager filed them. A manager can ask the SEC to keep some positions confidential for a time. This page uses SEC data and is not endorsed or certified by the SEC.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in Princeton, New Jersey

- [Pharmaceutical companies in Princeton, New Jersey](https://specstream.ai/data/businesses/pharmaceutical-companies/princeton-new-jersey-united-states)
- [Real estate firms in Princeton, New Jersey](https://specstream.ai/data/businesses/real-estate-firms/princeton-new-jersey-united-states)
- [Software development companies in Princeton, New Jersey](https://specstream.ai/data/businesses/software-development-companies/princeton-new-jersey-united-states)
- [Accounting firms in Princeton, New Jersey](https://specstream.ai/data/businesses/accounting-firms/princeton-new-jersey-united-states)
- [Banks and credit unions in Princeton, New Jersey](https://specstream.ai/data/businesses/banks-and-credit-unions/princeton-new-jersey-united-states)
- [Business consulting firms in Princeton, New Jersey](https://specstream.ai/data/businesses/business-consulting-firms/princeton-new-jersey-united-states)
